A Stanford-led team developed a machine-learning model that predicts donor death timing, reducing canceled liver transplants and improving resource use.
Key Details
- 1A machine-learning model predicts whether donors will die within 30–45 minutes after life support removal, enabling timely liver transplantation.
- 2The model was trained on over 2,000 cases from six US transplant centers and outperformed surgeons’ judgment (75% vs 65% accuracy).
- 3Futile procurement rates (resources spent without a successful transplant) dropped by 60% using the model.
- 4Missed transplant opportunities remained similar to surgeon judgment (just over 15%), but further model refinements lowered this to ~10% in recent tests.
- 5The model incorporates donor demographics, vitals, lab results, ventilator settings, and neurological assessments, and features a natural language interface for clinical data extraction.
- 6It is customizable to clinical and hospital preferences and is being adapted for heart and lung transplantation.
Why It Matters
This research demonstrates the growing potential of machine learning in high-stakes surgical decision-making, supporting better allocation of scarce organs and healthcare resources. Increased accuracy and efficiency can enhance patient outcomes, reduce waste, and potentially expand AI's role into more imaging-driven and perioperative workflows.
Source
EurekAlert
Related News
•EurekAlert
NIH Invests Additional $12.6M in USC-Led Imaging AI for Alzheimer's
NIH has renewed and expanded its support for a USC-led consortium developing AI to decode and treat Alzheimer's using imaging and genomic data.
•EurekAlert
USC Unveils Joint Biomedical Engineering Department Bridging Medicine, Engineering, and Imaging
USC's medical and engineering schools launch a joint biomedical engineering department to accelerate interdisciplinary research and innovation, including imaging and AI.
•EurekAlert
AI Predicts Risks for Outpatient Stem Cell Therapy in Myeloma
Researchers use machine learning to predict adverse events during stem cell therapy for multiple myeloma, improving outpatient safety.